Sale

Generic Drugs Market

Global Generic Drugs Market Size, Trends, Report, Forecast: By Brand: Pure Generic, Branded Generic; By Indications: Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory, Others; By Route of Administration: Oral, Others; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Generic Drugs Market Outlook

The global generic drugs market reached a value of almost USD 434.45 billion in 2023, driven by the significant rise in the cardiometabolic risk factors among the population. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032 to achieve a value of USD 703.41 billion by 2032.

 

Global Generic Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global generic drugs market is driven by the rising cardiometabolic risk factors across the globe. The United States is the leading regional market. This can be attributed to the implementation of rigorous reviews by the numerous regulatory bodies to ensure optimum standards during the manufacturing of these drugs, further aiding the market growth in the region.

 

Market Segmentation

Generic drugs are referred to as the bioequivalent of brand-name drugs on the basis of safety, strength, quality, stability, impact, intended use, dosage form, and the route of administration. These drugs are established to be safe and effective just as their already marketed brand-name formulation. Generic drug manufacturers are not required to invest in drug research or drug development and marketing, which makes these medicines cost-effective, thereby contributing to their widespread preference.

 

Generic Drugs Market by Drug Delivery

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The generic drugs market is segmented on the basis of application into:

  • CNS
  • Cardiovascular
  • Dermatology
  • Genitourinary/Hormonal
  • Respiratory
  • Rheumatology
  • Diabetes
  • Oncology
  • Others

Among all of these, cardiovascular diseases represent the largest segment in the market.

On the basis of drug delivery, the industry is divided into:

  • Oral
  • Injectables   
  • Dermal/Topical
  • Inhalers

Oral generic drugs at present account for a majority of the total market share.

On the basis of distribution channel, the industry is bifurcated into:

  • Retail Pharmacies
  • Hospital Pharmacies

Out of these, retail pharmacies represent a clear dominance in the global generic drugs market.

The report also covers the regional markets like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Generic Drugs Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The global generic drugs market is driven by the significant rise in the cardiometabolic risk factors among the population. In addition to this, due to various factors, such as changing dietary patterns, sedentary lifestyles, and hectic working schedules, there is a growing prevalence of diabetes, dyslipidaemia, hypertension, metabolic syndrome, and obesity. This has resulted in a considerable rise in the uptake of medicines, thereby accelerating the growth of the industry.

The global generic drugs market is further enhanced by the huge costs related to the medication of various chronic and lifestyle diseases, which have led to the increase in the consumer inclination toward affordable variants, further boosting the demand. Apart from this, the patent expiration of crucial blockbuster drugs, in conjunction with multiple favourable initiatives undertaken by the governments of several countries to promote the usage of generic drugs, is anticipated to propel the industry growth. Numerous regulatory bodies are implementing rigorous reviews to ensure optimum standards during the manufacturing of these drugs.

 

Competitive Landscape

The report gives a detailed analysis of the following key players in the global generic drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Brand
  • Indications
  • Route of Administration
  • End User
  • Distribution Channel
  • Region
Breakup by Brand
  • Pure Generic
  • Branded Generic
Breakup by Indications
  • Central Nervous System (CNS)
  • Cardiovascular
  • Dermatology
  • Oncology
  • Respiratory
  • Others
Breakup by Route of Administration
  • Oral
  • Topical
  • Parenteral
  • Others
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Centers
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Lupin
  • Endo International plc.
  • Aurobindo Pharma
  • Novartis AG
  • Hikma Pharmaceuticals PLC.
  • STADA Arzneimittel AG
  • Eli Lilly and Company
  • Aspen Holdings
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Generic Drug Market Overview 

    3.1    Global Generic Drug Market Historical Value (2017-2023) 
    3.2    Global Generic Drug Market Forecast Value (2024-2032)
4    Global Generic Drug Market Landscape
    4.1    Global Generic Drug Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Generic Drug Product Landscape
        4.2.1    Analysis by Brand
        4.2.2    Analysis by Indications
        4.2.3    Analysis by Route of Administration
5    Global Generic Drug Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Generic Drug Market Segmentation
    6.1    Global Generic Drug Market by Brand
        6.1.1    Market Overview
        6.1.2    Pure Generic
        6.1.3    Branded Generic
    6.2    Global Generic Drug Market by Indications
        6.2.1    Market Overview
        6.2.2    Central Nervous System (CNS)
        6.2.3    Cardiovascular
        6.2.4    Dermatology
        6.2.5    Oncology
        6.2.6    Respiratory
        6.2.7    Others
    6.3    Global Generic Drug Market by Route of Administration
        6.3.1    Market Overview
        6.3.2    Oral
        6.3.3    Topical
        6.3.4    Parenteral
        6.3.5    Others
    6.4    Global Generic Drug Market by End User
        6.4.1    Market Overview
        6.4.2    Hospitals
        6.4.3    Homecare
        6.4.4    Specialty Centers
        6.4.5    Others
    6.5    Global Generic Drug Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacy
        6.5.3    Online Pharmacy
        6.5.4    Retail Pharmacy
    6.6    Global Generic Drug Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Generic Drug Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Generic Drug Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Generic Drug Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Generic Drug Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Generic Drug Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis 
    14.1     Analysis by Trial Registration Year 
    14.2    Analysis by Trial Status 
    14.3    Analysis by Trial Phase 
    14.4    Analysis by Therapeutic Area 
    14.5    Analysis by Geography 
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    Teva Pharmaceuticals Industries Ltd.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Mylan NV
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Novartis AG
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Pfizer Inc.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Sun Pharmaceutical Industries Ltd.
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Fresenius SE & Co. KGaA
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Lupin
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Endo International plc.
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Aurobindo Pharma
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Novartis AG
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Hikma Pharmaceuticals PLC.
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    STADA Arzneimittel AG
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Eli Lilly and Company
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Aspen Holdings
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
19    Global Generic Drug Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global market for generic drugs reached a total of USD 434.45 billion in 2023.

The market is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032 to reach a value of USD 703.41 billion by 2032.

The major drivers of the industry include rising disposable incomes, increasing population, rising cardiometabolic risk factors, and the implementation of rigorous reviews by the numerous regulatory bodies to ensure optimum standards during the production of these drugs.

Various favourable initiatives undertaken by the governments of multiple countries is expected to be a key trend guiding the growth of the industry.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.

Cardiovascular disease is the dominant application segment in the industry. 

Oral generic drugs are the leading delivery type of the product in the industry. 

The retail pharmacies account for the largest market share, among other distribution channels in the industry.

The leading players in the industry are Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd., and Fresenius Kabi AG, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER